TOBI® PODHALER® + TOBI® + Bethkis® + Cayston®
Pre-clinicalCompleted 2 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pseudomonas Aeruginosa in Cystic Fibrosis
Conditions
Pseudomonas Aeruginosa in Cystic Fibrosis
Trial Timeline
May 5, 2015 → Dec 31, 2021
NCT ID
NCT02449031About TOBI® PODHALER® + TOBI® + Bethkis® + Cayston®
TOBI® PODHALER® + TOBI® + Bethkis® + Cayston® is a pre-clinical stage product being developed by Viatris for Pseudomonas Aeruginosa in Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02449031. Target conditions include Pseudomonas Aeruginosa in Cystic Fibrosis.
What happened to similar drugs?
1 of 5 similar drugs in Pseudomonas Aeruginosa in Cystic Fibrosis were approved
Approved (1) Terminated (2) Active (3)
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02449031 | Pre-clinical | Completed |
Competing Products
8 competing products in Pseudomonas Aeruginosa in Cystic Fibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0292 | AstraZeneca | Phase 2 | 42 |
| tobramycin + tobramycin | Novartis | Phase 3 | 40 |
| Tobramycin inhalation powder | Novartis | Phase 3 | 40 |
| TIS or TIP | Novartis | Approved | 35 |
| AZLI + Placebo | Gilead Sciences | Phase 3 | 32 |
| Ciprofloxacin (Cipro, BAYQ3939) | Bayer | Phase 1 | 26 |
| Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer. + Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | Insmed | Phase 3 | 37 |
| IC43 + Placebo | Valneva SE | Phase 2/3 | 32 |